NanoString Plans to Take Second-Gen nCounter Technology through FDA | GenomeWeb

By Justin Petrone

Inching closer to having a US Food and Drug Administration-cleared offering on the market, NanoString Technologies last week debuted its second-generation nCounter Analysis System, upon which it will submit tests to the agency for review, according to a company official.

"It is the basis for our diagnostic platform," Chris Grimley, the Seattle-based company's vice president of marketing, said last week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.